Close Menu

NEW YORK — Envisagenics said today that it has received a $300,000 grant from the National Cancer Institute to refine its cloud-based RNA splicing analytics platform for the discovery of novel immuno-oncology therapeutics.

The platform, called SpliceCore, is designed to map patient RNA sequencing datasets to a collection of over 5 million alternative splicing errors in order to pinpoint ones that cause disease. Machine learning algorithms are then used to prioritize druggable splicing events and identify novel RNA-based drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Sponsored by

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.